• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

    2/13/24 5:01:03 PM ET
    $CERS
    EDP Services
    Technology
    Get the next $CERS alert in real time by email
    SC 13G/A 1 tv0576-ceruscorp.htm SCHEDULE 13G/A ceruscorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 4)*

    Name of issuer:  Cerus Corp

    Title of Class of Securities:  Common Stock

    CUSIP Number:  157085101

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  157085101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    288,409

    7.  SOLE DISPOSITIVE POWER

    9,514,946

    8.  SHARED DISPOSITIVE POWER

    355,725

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,870,671

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.45%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Cerus Corp

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1220 Concord Avenue, Suite 600
    Concord, CA 94520

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    157085101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $CERS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERS

    DatePrice TargetRatingAnalyst
    4/12/2024$5.00Buy
    Craig Hallum
    1/20/2023Buy → Neutral
    BTIG Research
    1/17/2023$3.75Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $CERS
    SEC Filings

    See more
    • Cerus Corporation filed SEC Form 8-K: Leadership Update

      8-K - CERUS CORP (0001020214) (Filer)

      6/23/25 4:32:36 PM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - CERUS CORP (0001020214) (Filer)

      6/9/25 1:39:17 PM ET
      $CERS
      EDP Services
      Technology
    • SEC Form SD filed by Cerus Corporation

      SD - CERUS CORP (0001020214) (Filer)

      5/30/25 4:01:40 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Cerus with a new price target

      Craig Hallum initiated coverage of Cerus with a rating of Buy and set a new price target of $5.00

      4/12/24 8:00:30 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus downgraded by BTIG Research

      BTIG Research downgraded Cerus from Buy to Neutral

      1/20/23 10:02:56 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus downgraded by Stephens with a new price target

      Stephens downgraded Cerus from Overweight to Equal-Weight and set a new price target of $3.75

      1/17/23 7:57:35 AM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Financials

    Live finance-specific insights

    See more
    • Cerus Corporation Announces First Quarter 2025 Financial Results

      First quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million First Quarter 2025 Total Revenue of $48.9 Million Including Government Contract Revenue of $5.6 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced today financial results for the first quarter ended March 31, 2025, and provided a business update. "We are off to a strong start in 2025, executing against our stated goals and making meaningful progress in advancing Cerus' mission to transform the safety and availability of transfused blood components," said William "Obi" Greenman, Cerus' president an

      5/1/25 4:00:00 PM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025

      Cerus Corporation (NASDAQ:CERS) announced today that its first quarter 2025 financial results will be released on Thursday, May 1, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay wi

      4/17/25 8:30:00 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results

      Full-Year and Fourth Quarter 2024 Product Revenues Increased 15% and 9%, respectively, from Prior Year Periods Fourth straight quarter of positive operating cash flows Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 – $200 million Cerus Corporation (NASDAQ:CERS) today announced financial results for its full year and fourth quarter ended December 31, 2024. Recent highlights include: Total revenue for full-year 2024 and fourth quarter 2024 was comprised of (in thousands, except %): Three Months Ended           Twelve Months Ended         December 31,   Change   December 31,   Change   Unaudited  

      2/20/25 4:00:00 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cerus Corporation Celebrates World Blood Donor Day 2025

      Cerus Corporation (NASDAQ:CERS) is proud to announce its celebration of World Blood Donor Day 2025. In 2005, the World Health Assembly designated June 14th as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. This year's theme, "Give blood, give hope: together we save lives" is a reminder that hope is something we can all share. Cerus is proud to promote blood safety and expand donor eligibility, helping more people give, and more people receive the transfusions they need. The Company salutes the individuals, communities, and countries working together to make blood safety and availability a reality.

      6/13/25 4:01:00 PM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

      Cerus Corporation (NASDAQ:CERS) announced today that members of the management team are scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, Florida, on Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time. A live webcast of the presentation can be accessed via the Events & Presentation section of Cerus' Investor Relations website at ir.cerus.com. A replay of the webcast will be available on Cerus Investor Relations website shortly after the event for 30 days. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, Ca

      6/3/25 4:30:00 PM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan

      Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells Cerus Corporation (NASDAQ:CERS) today announced it will showcase the latest INTERCEPT Blood System clinical data at the 35th Regional International Society of Blood Transfusion (ISBT) Congress being held May 31 to June 4, 2025, in Milan. "The breadth of data being presented this year underscores the broad applicability of the INTERCEPT system for platelets, plasma, and cryoprecipitated fibrinogen complex as well as the potential benefit for red blood cells," said Richard J. Benjamin, Cerus' chief medical officer. "Importantly, w

      5/29/25 8:30:00 AM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Witney Frank was granted 60,000 shares, increasing direct ownership by 27% to 280,059 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      6/4/25 6:53:35 PM ET
      $CERS
      EDP Services
      Technology
    • Director Moore Timothy L. was granted 60,000 shares, increasing direct ownership by 41% to 205,073 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      6/4/25 6:48:52 PM ET
      $CERS
      EDP Services
      Technology
    • Director Swisher Daniel N Jr was granted 60,000 shares, increasing direct ownership by 41% to 207,045 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      6/4/25 6:44:28 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gregory Dean A. bought $2,932 worth of shares (1,725 units at $1.70), increasing direct ownership by 3% to 61,725 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      1/2/25 5:46:11 PM ET
      $CERS
      EDP Services
      Technology
    • Shan Hua bought $4,975 worth of shares (2,500 units at $1.99), increasing direct ownership by 8% to 32,386 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      5/14/24 6:30:46 PM ET
      $CERS
      EDP Services
      Technology
    • Nachtsheim Jami K bought $3,578 worth of shares (2,000 units at $1.79), increasing direct ownership by 2% to 108,362 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      5/13/24 5:09:19 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Leadership Updates

    Live Leadership Updates

    See more
    • Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors

      Cerus Corporation (NASDAQ:CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year. "We are very pleased to welcome Mr. Gregory to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, h

      7/2/24 4:00:00 PM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer

      Cerus Corporation (NASDAQ:CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. "We are excited to welcome Alicia to the Cerus team," said William "Obi" Greenman, Cerus' president and chief executive officer. "As we advance on key global commercial and pipeline initiatives, our talent, leadership and organization structure across all levels of the organization w

      9/27/23 8:30:00 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors

      Cerus Corporation (NASDAQ:CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors. "We are pleased to welcome Dr. Shan to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Dr. Shan is an accomplished, leading voice in the transfusion community, with more than twenty-five years of experience in the field, bringing a wealth of knowledge and insight to our Board. In addition, Dr. Shan has extensive experience with international blood bank practices including the Chinese transfusion market. We expect to benefit from Dr. Shan's expertise as we co

      7/5/22 5:00:00 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cerus Corporation

      SC 13G/A - CERUS CORP (0001020214) (Subject)

      11/12/24 9:53:11 AM ET
      $CERS
      EDP Services
      Technology
    • SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

      SC 13G/A - CERUS CORP (0001020214) (Subject)

      2/14/24 4:21:51 PM ET
      $CERS
      EDP Services
      Technology
    • SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

      SC 13G/A - CERUS CORP (0001020214) (Subject)

      2/13/24 5:01:03 PM ET
      $CERS
      EDP Services
      Technology